Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

a relative reduction of 32% in CAPACITY 2 and 10% in CAPACITY 1.

To better understand the primary efficacy outcome, InterMune conducted an exploratory analysis that interrogated the time course of the pirfenidone treatment effect. The results of an exploratory repeated measures analysis of ranked change from baseline, assessing treatment effect over the full duration of the study showed that pirfenidone reduced the decline in FVC in both studies (CAPACITY 2, p=0.004 and CAPACITY 1, p=0.001).

Secondary Efficacy Endpoint Results

In CAPACITY 2, treatment with pirfenidone was associated with a statistically significant effect on the pre-specified secondary endpoints of PFS (p=0.023) and Categorical Change in FVC (p=0.001) when compared to placebo. A PFS event was defined in the study protocol as the time to death, a 10% decrease in FVC or a 15% decrease in DLco. In CAPACITY 1, pirfenidone treatment was associated with a treatment effect in the pre-specified secondary endpoint of Six-Minute Walk Test distance (p=0.001) when compared to placebo. There were no other statistically significant findings on any of the other pre-specified secondary endpoints in either study and pirfenidone treatment was not associated with a worse outcome on any endpoints.

Analyses of pooled data for the pre-specified secondary endpoints of both CAPACITY studies showed a treatment effect favoring pirfenidone on three: PFS (p=0.029); Categorical FVC Change (p=0.003) and Six-Minute Walk Test distance (p=0.001). Although pooled analyses of secondary endpoints were pre-specified in the study protocols, these analyses are nonetheless considered exploratory because the primary endpoint of both studies was not met.

The pooled analysis of Categorical FVC Change showed that 30% fewer patients experienced a 10% or greater decrease in FVC at week 72 in the pirfenidone group than in the placebo group. This magnitu
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
(Date:7/30/2015)... and VANCOUVER , July 30, ... announced today that it will report its second quarter ... management will host a conference call and live webcast ... of financial results, clinical development programs and a general ... log on to the Investor Relations page of the ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
(Date:8/3/2015)... ... August 03, 2015 , ... ... to decline by 39 percent, according to market research compiled for the National ... from the U.S. Department of Labor, Bureau of Labor Statistics. As the number ...
(Date:8/3/2015)... ... August 03, 2015 , ... Constantin Vasilica, 48 from Romania ... injury caused by diabetes after many years of suffering and using medications with strong ... didn’t want to ask for extra time off or wait longer hours in the ...
(Date:8/3/2015)... ... ... The American Institute of Architects (AIA) and ... a wide range of initiatives ranging from code development and compliance to sustainability ... membership, consisting of practicing design professionals, code officials, and the building industry representatives, ...
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I ... childhood cancers. The study is led by Kenneth G. Lucas, M.D. , chief ... Louisville in collaboration with colleagues at Kosair Children’s Hospital and in the ...
(Date:8/1/2015)... ... , ... AlignLife Office Coordinator Heather Pugh earned the position of ... at this natural health care center in Winamac. , "Oftentimes patients are in pain ... is vital to our approach because we want to focus on the patient wants ...
Breaking Medicine News(10 mins):Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:New Patient Advocate Enhances Natural Health Care 2
... Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... R788, a novel, oral Syk kinase inhibitor, in ... study showed that R788 (tamatinib fosdium) can improve,platelet ... body attacks and,destroys its own blood platelets. ...
... health assistance in disaster zones is to be presented ... Dr Johan von Schreeb shows that international assistance is ... assessment having been made of the affected population. ... in a number of disaster situations. He examined the ...
... disease, but most remain unaware of it, hampering efforts ... transplant, according to a study funded by the National ... Journal of the American Medical Association. , ... of the U.S. population now have chronic kidney ...
... Corporation,(Amex: CVM ) announced today that its Board ... ensure that all of its stockholders,receive fair and equal ... of CEL-SCI. Geert Kersten, Chief Executive Officer, said ... stage for a cancer indication that has a,multi- billion ...
... the progression of chronic hepatitis C and advanced liver ... to eradicate the disease, a national study in which ... found. , Patients in the trial who were treated ... levels and liver inflammation, but the trial unequivocally demonstrated ...
... children , FRIDAY, Nov. 9 (HealthDay News) -- Certain ... according to studies presented this week at the American ... study found that abatacept, used to treat adults with ... treatment for children and adolescents with severe, treatment-resistant juvenile ...
Cached Medicine News:Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 2Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 3Health News:Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study 4Health News:Humanitarian assistance often lacks needs assessment 2Health News:Chronic kidney disease rises while most people with the condition remain unaware 2Health News:CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan 2Health News:CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan 3Health News:Interferon does not slow or stop hepatitis C from worsening, study finds 2Health News:Drugs Can Ease Juvenile Rheumatoid Arthritis 2
... FSH EIA Test is based ... solid phase enzyme-linked immunosorbent assay. ... monoclonal anti-FSH for solid phase ... anti-alpha FSH in the antibody-enzyme ...
Lyophilized, tri-level assayed human serum-based control, Low, intermediate and high levels, Lot-specific target values provided, Suitable for use with RIA, EIA and chemiluminescent,methodo...
... Hormone (FSH) is intimately involved in the ... of the gonadal tissues, which synthesize and ... The levels of circulating FSH is controlled ... feedback relationship. The FSH Quantitative Test ...
Complete product line for typing all classical HLA loci including A, B, C DRA, DRB1, DRB3, DRB4, DRB5, DQA, DQB1, DPA1, and DPB1....
Medicine Products: